In accordance, our results revealed a negative DPP4 regulation under iSGLT2 exposure, with a significant peptidase overexpression when SIRT3 was silenced, suggesting DPP4 as a novel molecular target of SGLT2 and unveiling its value as therapeutic tool in CRC. The gene discussed is SIRT3; the disease is colorectal carcinoma.